REGENERON PHARMACEUTICALS (REGN)
US75886F1075 - Common Stock
| 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | 2019 (2019-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 16.24B | 3.11B | 2.89B | 2.19B | 1.62B | |||
| Marketable Securities | 8.11B | 4.64B | 2.81B | 1.39B | 1.60B | |||
| Receivables | 5.67B | 5.33B | 6.04B | 4.12B | 2.67B | |||
| Inventories | 2.58B | 2.40B | 1.95B | 1.92B | 1.42B | |||
| Other Current Assets | 386.60M | 411.00M | 332.00M | 161.00M | 387.00M | |||
| Total Current Assets | 19.48B | 15.88B | 14.02B | 9.78B | 7.69B | |||
| Non-Current Assets | ||||||||
| PPE Net | 4.22B | 3.76B | 3.48B | 3.22B | 2.89B | |||
| Investments And Advances | 5.47B | 6.64B | 6.88B | 3.19B | 3.31B | |||
| Intangibles | 1.04B | 916.00M | N/A | N/A | N/A | |||
| Other Non-Current Assets | 2.87B | 2.01B | 1.06B | 968.00M | 913.00M | |||
| Total Non-Current Assets | 13.60B | 13.33B | 11.42B | 7.38B | 7.12B | |||
| TOTAL ASSETS | 33.08B | 29.21B | 25.43B | 17.16B | 14.80B | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Current Portion Of LT Debt. | N/A | 0.00 | 720.00M | N/A | N/A | |||
| Accrued Expenses | 2.36B | 2.07B | 1.88B | 1.50B | 1.04B | |||
| Accounts Payable | 4.43B | 589.00M | 564.00M | 476.00M | 418.00M | |||
| Other Current Liabilities | 458.90M | 478.00M | 768.00M | 720.00M | 641.00M | |||
| Total Current Liabilities | 3.42B | 3.14B | 3.93B | 2.70B | 2.10B | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 2.70B | 2.70B | 1.98B | 2.70B | 714.00M | |||
| Other Non-Current Liabilities | 980.80M | 708.00M | 754.00M | 745.00M | 905.00M | |||
| Total Non-Current Liabilities | 3.68B | 3.41B | 2.73B | 3.44B | 1.62B | |||
| TOTAL LIABILITIES | 7.11B | 6.55B | 6.67B | 6.14B | 3.72B | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | 27.26B | 23.31B | 18.97B | 10.89B | 7.38B | |||
| Additional Paid In Capital | 11.35B | 9.95B | 8.09B | 6.72B | 4.43B | |||
| Common Shares | 101.80K | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Treasury Stock | -12.56B | -10.35B | -8.26B | -6.61B | -740.00M | |||
| Other Shareholders' Equity | -80.90M | -239.00M | -26.00M | 29.00M | 21.00M | |||
| Shares Outstanding | 109.40M | 110.00M | 109.00M | 107.00M | 110.00M | |||
| Tangible Book Value per Share | 227.92 | 197.71 | 172.19 | 103.04 | 100.82 | |||
| Total Shareholders' Equity | 25.97B | 22.66B | 18.77B | 11.03B | 11.09B | |||
| TOTAL LIABILITIES AND EQUITY | 33.08B | 29.21B | 25.43B | 17.16B | 14.80B | |||
| Statistics | ||||||||
| Debt/Equity | 0.10 | 0.12 | 0.11 | 0.24 | 0.06 | |||
| Current Ratio | 5.69 | 5.06 | 3.56 | 3.63 | 3.67 | |||
| Return On Assets (ROA) | 11.95% | 14.85% | 31.75% | 20.47% | 14.29% | |||
| Return On Equity (ROE) | 15.22% | 19.14% | 43.02% | 31.86% | 19.08% | |||
| Return On Invested Capital (ROIC) | 11.28% | 15.13% | 32.87% | 19.53% | 13.74% | |||
| Return On Invested Capital Ex Cash (ROICexc) | 63.09% | 21.52% | 44.72% | 25.98% | 18.39% | |||
| Return On Invested Capital Ex Cash + Goodwill (ROICexcg) | 78.46% | 22.65% | 44.72% | 25.98% | 18.39% | |||
All data in USD